

Open Peer Review on Qeios

Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201

National Cancer Institute

Source

National Cancer Institute. <u>Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201</u>.

NCI Thesaurus. Code C84872.

A non-small cell lung cancer (NSCLC) vaccine containing modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Upon subcutaneous administration, non-small cell lung cancer mRNA-derived vaccine CV9201 may stimulate the immune system to mount a cytotoxic, antigen-specific T lymphocyte response (CTL) against NSCLC cells. The modified mRNAs in this vaccine are taken up by cells after injection and exhibit enhanced translational potency. The five tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells.

Qeios ID: 4CJEF5 · https://doi.org/10.32388/4CJEF5